Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma

Table 1 Correlations between MACC1 mRNA expression and clinicopathologic features of HCC

Characteristics	No. patients	MACC1 mRNA high level	P value*
Gender
Female	12	58.3% (7/12)	0.169
Male	116	37.9% (44/116)
Age (years)^†
≤ 50	65	44.6% (29/65)	0.263
> 50	63	34.9% (22/63)
HBsAg status
Negative	18	33.3% (6/18)	0.543
Positive	110	40.9% (45/110)
AFP (μg/l)
≤ 400	78	32.1% (25/78)	0.025
> 400	50	52.0% (26/50)
Cirrhosis
No	13	30.8% (4/13)	0.481
Yes	115	40.9% (47/115)
Child-Pugh classification^‡
A	116	39.7% (46/116)	0.892
B	12	41.7% (5/12)
Tumour size (cm)
≤ 5	50	40.0% (20/50)	0.977
> 5	78	39.7% (31/78)
Multiple tumours
No	91	39.6% (36/91)	0.918
Yes	37	40.5% (15/37)
Tumour capsule
Complete	32	34.4% (11/32)	0.466
No/incomplete	96	41.7% (40/96)
Vascular invasion
No	98	37.8% (37/98)	0.383
Yes	30	46.7% (14/30)
Edmondson-Steiner grade
I/II	69	34.8% (24/69)	0.206
III/IV	59	39.8% (27/59)
TNM stage
I	67	31.3% (21/67)	0.077
II	26	42.3% (11/26)
III	35	54.3%(19/31)

MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen.
*Chi-square or Fisher's exact test.
^†Patients were divided according to the median age.
^‡No patients with Child-Pugh C were included.

ISSN: 1479-5876